Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at tough leukemia

NCT ID NCT07257640

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called IL-5 CAR-T cell therapy for people with a rare and hard-to-treat blood cancer called eosinophilic leukemia. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to check safety and see if the treatment can shrink or control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic eosinophilic leukemia hematologic disorder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC DISEASES NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of medical college of zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••